Financial HighlightsFull Year 2025 Financial ResultsFor the year ended June 30, 2025, the Company reported total expenses of $41.8 million compared to $22.5 million for the year ended June 30, 2024. General and administrative expenses totaled $23.4 million in 2025 compared to $7.0 million in 2024. The loss from operations for the year ended June 30, 2025, was $37.9 million compared to $21.8 million for the prior year. As of June 30, 2025, the Company had $97.7 million in cash and cash equivalents. About Benitec Biopharma, Inc.Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California.